Market Movers (8-K)
See all →NASDAQ
Myriad Genetics announced the approval of one-time stock option awards for key executive officers to ensure leadership continuity and support strategic initiatives.
NASDAQ
Myriad Genetics disclosed a cybersecurity incident on November 2, 2026, involving unauthorized network access, prompting an ongoing investigation and temporary system suspensions.
NASDAQ
Myriad Genetics announced third quarter 2026 financial results, raising full-year revenue guidance while also entering an agreement to sell its Prenatal Health business to Labcorp.
NASDAQ
Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business to Laboratory Corporation of America for $210 million in cash plus inventory value.
NASDAQ
Myriad Genetics reports the departure of its Chief Commercial Officer, Brian Donnelly, detailing a severance package including a lump sum payment and equity vesting acceleration.
NASDAQ
Myriad Genetics announced the promotion of Vishal Sikri to Executive Vice President Commercial and the departure of Chief Commercial Officer Brian Donnelly, while reaffirming its full-year 2026 financial guidance.
Quarterly Earnings (10-Q)
See all →NASDAQ
Myriad Genetics reports a revenue decrease for Q3 2026, driven by a decline in Prenatal Health, while preparing to sell its Prenatal Health business for $210 million.
Worse than expected
NASDAQ
Myriad Genetics reports a revenue decrease in Q2 2026 driven by estimate changes and reimbursement pressures, while increasing sales and marketing investments.
Worse than expected
NASDAQ
Myriad Genetics reported a 2.3% increase in revenue for the first quarter of 2026, reaching $200.4 million, but experienced a significant widening of its net loss to $34.1 million.
Worse than expected
NASDAQ
Myriad Genetics reported a wider net loss in the third quarter and first nine months of 2025, driven by significant goodwill and intangible asset impairment charges, despite some revenue growth in Hereditary Cancer and Prenatal segments.
Worse than expected
Capital raise
NASDAQ
Myriad Genetics reported a significant net loss in the second quarter of 2025, primarily driven by a $316.7 million goodwill and intangible asset impairment charge, despite slight revenue growth.
Capital raise
Worse than expected
NASDAQ
Myriad Genetics' Q1 2025 revenue decreased to $195.9 million, impacted by changes in pharmacogenomics coverage and leadership transitions.
Worse than expected
Annual Reports (10-K)
NASDAQ
Myriad Genetics reported a significant net loss of $365.9 million in 2025, driven by substantial impairment charges and a 2% revenue decrease, despite strategic advancements in its testing portfolio.
Capital raise
Worse than expected
NASDAQ
Myriad Genetics announces its FY2024 financial results, highlighting revenue growth across key segments while addressing challenges related to reimbursement coverage.
Worse than expected
NASDAQ
Myriad Genetics has entered into a 15-year lease agreement for a new facility in Salt Lake City, with options for expansion and early termination under specific conditions.
Delay expected
Insider Trading (Form 4)
See all →NASDAQ
Mark Steven Davis, a Director of Myriad Genetics Inc, sold 6,100 shares of common stock on November 18, 2026 for $5.62 per share.
NASDAQ
Raj Jampa, Chief Technology Officer of Myriad Genetics Inc, received 58,560 shares of common stock on November 6, 2026.
NASDAQ
Vishal Sikri, EVP, Commercial of Myriad Genetics Inc, received 53,236 shares of common stock on November 6, 2026.
NASDAQ
Shereen Solaiman, Chief People Officer of Myriad Genetics Inc, received 83,049 shares of common stock on November 6, 2026.
NASDAQ
Jennifer Lynne Fox, Chief Legal & Corp Strategy of Myriad Genetics Inc, received 139,267 shares of common stock on November 6, 2026.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc, received 92,632 shares of common stock on November 6, 2026.
Proxy Statements (Def-14A)
NASDAQ
Myriad Genetics, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors, ratify auditor selection, and approve executive compensation and equity plans.
Worse than expected
NASDAQ
Myriad Genetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
DEF: Myriad Genetics Announces Leadership Transition and Highlights 2024 Achievements in Proxy Statement
Myriad Genetics' proxy statement reveals a leadership transition with Sam Raha succeeding Paul Diaz as CEO, alongside strong 2024 financial performance and strategic advancements.
Worse than expected
NASDAQ
Myriad Genetics has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.
NASDAQ
Myriad Genetics highlights 11% revenue growth in 2023 and strategic advancements in molecular diagnostics and precision medicine.
Capital raise
Schedule 13G - Passive Investments
See all →NASDAQ
BlackRock Portfolio Management LLC has updated its beneficial ownership filing for Myriad Genetics Inc., reporting a 10.4% stake.
NASDAQ
Glenview Capital Management and Larry Robbins have filed an amended Schedule 13G, reporting no beneficial ownership of Myriad Genetics Inc. common stock as of June 30, 2026.
NASDAQ
State Street Corporation has disclosed beneficial ownership of 5.3% of Myriad Genetics Inc. common stock as of June 30, 2026.
NASDAQ
State Street Corporation has reported beneficial ownership of 4.7% of Myriad Genetics Inc. common stock as of March 31, 2026.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7,976,163 shares, representing 8.5% of Myriad Genetics Inc.'s common stock.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Myriad Genetics Inc. following an internal realignment.
Worse than expected